Mr. Thomas Smeenk reports

HEMOSTEMIX ANNOUNCES ARBITRATION AWARD OF CAD $315,684 PLUS PRIVATE PLACEMENT

On Aug. 10, 2023, Hemostemix Inc. received a final cost award from the International Center for Dispute Resolution (ICDR), International Abritration Tribunal, in the matter of arbitration between Dr. Elmar Burchardt versus Hemostemix. The award stipulates Dr. Burchardt is to pay Hemostemix $315,684 of its costs. Certified, for the purposes of Article I of the New York Convention of 1958 on the Recognition and Enforcement of Foreign Arbitral Awards, the final award was made in Calgary, Alta., Canada.

The company is continuing its non-brokered private placement of up to 10 million units priced at 12 cents each. Each unit consists of one common share in the capital of the company and one-half of one common share purchase warrant, with each full warrant entitling the holder to acquire one common share at a price of 25 cents per common share for a period of 24 months from the closing of the offering, subject to the accelerated expiry provision described in its previous news releases. The offering is subject to all necessary regulatory approvals including acceptance from the exchange.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy company, founded in 2003.

We seek Safe Harbor.